Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688319'
s FCF Margin % Range Over the Past 10 Years
Min: -30669.57 Med: -38.24 Max: 0.95
Current: 0.03
During the past 13 years, the highest FCF Margin % of Chengdu Olymvax Biopharmaceuticals was 0.95%. The lowest was -30669.57%. And the median was -38.24%.
SHSE:688319's FCF Margin % is ranked better than 74.63% of 950
companies
in the Biotechnology industry
Industry Median: -79.025
vs SHSE:688319: 0.03
Chengdu Olymvax Biopharmaceuticals FCF Margin % Related Terms
Chengdu Olymvax Biopharmaceuticals FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688319 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Chengdu Olymvax Biopharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Olymvax Biopharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Olymvax Biopharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Chengdu Olymvax Biopharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a FCF Margin % of -30.63% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. According to the industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #241 out of 950 companies in the Biotechnology industry, placing it in the top 25.4%.
Is Chengdu Olymvax Biopharmaceuticals' FCF Margin % too high?
Chengdu Olymvax Biopharmaceuticals' current FCF Margin % is -30.63%. Based on the distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #241 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #241 out of 950 companies for FCF Margin %. This puts Chengdu Olymvax Biopharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. Chengdu Olymvax Biopharmaceuticals's current FCF Margin % is -30.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥23.13, compared to a current price of ¥27.08 — trading 17.1% above its estimated fair value. The current FCF Margin % is -30.63%. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current FCF Margin % is -30.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued.
The current stock price of ¥27.08 is trading 17.1% above its estimated GF Value™ of ¥23.13.
GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.
Key valuation signals for SHSE:688319:
FCF Margin %: -30.63%
GF Value™: ¥23.13 vs. price of ¥27.08 (17.1% above fair value)
No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Olymvax Biopharmaceuticals Business Description
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
73GF Score
Get the complete analysis for SHSE:688319
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688319 has been successfully added to your 
